CRIS — Curis Inc
NASDAQ · Healthcare · Biotechnology
$1.42
+$0.00 (+0.00%)
Curis Inc (CRIS) is a biotechnology company listed on NASDAQ. It is led by James E. Dentzer, based in Building C, Lexington, MA, United States, 02421, with about 20 employees. Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Latest reported CRIS revenue for 2025-09-30 was $3.2M. Net income was -$7.7M. Revenue was up 15.5% from 2025-06-30 to 2025-09-30. CRIS currently screens at market cap $22.1M.
Use this CRIS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CRIS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CRIS SEC filings page. Lician reads the product cache first so this HTML stays unique to Curis Inc even when a live quote feed is slow.
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
CRIS Key Statistics
Market Cap
$22.10M
Volume
82,472
Previous Close
$1.58
Day Range
$1.51 – $1.65
EPS
-$6.88
Revenue
$10.91M
Net Income
-$43.39M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+8.8%
Profit Margin
-397.8%
Employees
20
CRIS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $10.91M | $10.02M | $10.16M | $10.65M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$43.39M | -$47.41M | -$56.67M | -$45.44M |
| EPS (Diluted) | -$6.88 | -$8.96 | -$12.14 | $0.50 |
Total Assets
$41.27M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$20.00M
Operating Cash Flow
-$39.56M
Free Cash Flow
$0.00
Curis Inc Company Information
- President, CEO, Secretary, Treasurer & Director
- James E. Dentzer
- Headquarters
- Building C, Lexington, MA, United States, 02421
- Website
- www.curis.com
- Phone
- 617 503 6500
- IPO / Founded
- 2000-08-01
- Sector
- Healthcare
- Industry
- Biotechnology